IceCure Medical Ltd
ICCM.TA
Tel Aviv Stock Exchange425.90
ILA
+0.50
- -
IceCure Medical Ltd
ICCM.TA
(Tel Aviv Stock Exchange)
Recent
price
425.90
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- IceCure Medical Ltd (Nasdaq: ICCM; TASE: ICCM.TA) develops and commercializes liquid-nitrogen-based cryoablation systems for the minimally invasive treatment of benign and malignant tumors in women's health and interventional oncology; core products include the ProSense single-probe system for breast tumors and other indications such as kidney, lung, liver, bone, prostate, skin lesions, and gynecological conditions, the IceSense3 system for urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology, the commercially available XSense system with CryoProbes for general surgery, dermatology, neurology, ENT, and additional cryoablation applications, and developmental-stage MultiSense multi-probe system for larger or multiple tumors. Founded in 2006 and headquartered in Caesarea, Israel, the company markets its technologies worldwide, including in the US, Europe, Asia, and recently Switzerland where ProSense received regulatory approval in 2025 for breast, lung, liver, and kidney cancer indications; it maintains US operations and partnerships such as with Terumo Corporation in Japan, anticipating a ProSense regulatory submission there in the first half of 2026. Recent developments encompass FDA marketing authorization in 2025 for ProSense in treating low-risk early-stage breast cancer in women aged 70 and older, a $10 million rights offering in 2025 to fund expansion, new clinical publications from the independent THERMAC and ICE3 trials affirming high ablation rates, low recurrence (3.1% at five years), and 95-99% satisfaction among patients and physicians, alongside a strong presence at EUSOBI 2025 showcasing de-escalation studies from Italy, Spain, and Turkey.